256 related articles for article (PubMed ID: 32171102)
1. Dually functional hollow ceria nanoparticle platform for intraocular drug delivery: A push beyond the limits of static and dynamic ocular barriers toward glaucoma therapy.
Luo LJ; Nguyen DD; Lai JY
Biomaterials; 2020 Jun; 243():119961. PubMed ID: 32171102
[TBL] [Abstract][Full Text] [Related]
2. Effects of shell thickness of hollow poly(lactic acid) nanoparticles on sustained drug delivery for pharmacological treatment of glaucoma.
Nguyen DD; Luo LJ; Lai JY
Acta Biomater; 2020 Jul; 111():302-315. PubMed ID: 32428681
[TBL] [Abstract][Full Text] [Related]
3. Harnessing the tunable cavity of nanoceria for enhancing Y-27632-mediated alleviation of ocular hypertension.
Luo LJ; Nguyen DD; Lai JY
Theranostics; 2021; 11(11):5447-5463. PubMed ID: 33859757
[No Abstract] [Full Text] [Related]
4. Montmorillonite/chitosan nanoparticles as a novel controlled-release topical ophthalmic delivery system for the treatment of glaucoma.
Li J; Tian S; Tao Q; Zhao Y; Gui R; Yang F; Zang L; Chen Y; Ping Q; Hou D
Int J Nanomedicine; 2018; 13():3975-3987. PubMed ID: 30022821
[TBL] [Abstract][Full Text] [Related]
5. State of the art clinical efficacy and safety evaluation of N-acetylcarnosine dipeptide ophthalmic prodrug. Principles for the delivery, self-bioactivation, molecular targets and interaction with a highly evolved histidyl-hydrazide structure in the treatment and therapeutic management of a group of sight-threatening eye diseases.
Babizhayev MA; Kasus-Jacobi A
Curr Clin Pharmacol; 2009 Jan; 4(1):4-37. PubMed ID: 19149498
[TBL] [Abstract][Full Text] [Related]
6. Cubic and hexagonal liquid crystal gels for ocular delivery with enhanced effect of pilocarpine nitrate on anti-glaucoma treatment.
Xingqi W; Yong Z; Xing L; Yang W; Jie H; Rongfeng H; Shuangying G; Xiaoqin C
Drug Deliv; 2019 Dec; 26(1):952-964. PubMed ID: 31544551
[TBL] [Abstract][Full Text] [Related]
7. [Effects of artificial tears on ocular surface in glaucomatous patients with long-term instillation of preserved antiglaucoma eye drops].
Makashova NV; Vasilieva AE; Kolosova OY
Vestn Oftalmol; 2018; 134(2):59-65. PubMed ID: 29771886
[TBL] [Abstract][Full Text] [Related]
8. Chitosan Nanoparticles as a Mucoadhesive Drug Delivery System for Ocular Administration.
Silva MM; Calado R; Marto J; Bettencourt A; Almeida AJ; Gonçalves LMD
Mar Drugs; 2017 Dec; 15(12):. PubMed ID: 29194378
[TBL] [Abstract][Full Text] [Related]
9. Gallic acid grafting effect on delivery performance and antiglaucoma efficacy of antioxidant-functionalized intracameral pilocarpine carriers.
Chou SF; Luo LJ; Lai JY
Acta Biomater; 2016 Jul; 38():116-28. PubMed ID: 27130273
[TBL] [Abstract][Full Text] [Related]
10. Recent Progress in Chitosan-Based Nanomedicine for Its Ocular Application in Glaucoma.
Albarqi HA; Garg A; Ahmad MZ; Alqahtani AA; Walbi IA; Ahmad J
Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36840002
[TBL] [Abstract][Full Text] [Related]
11. Development of Timolol-Loaded Galactosylated Chitosan Nanoparticles and Evaluation of Their Potential for Ocular Drug Delivery.
Zhao R; Li J; Wang J; Yin Z; Zhu Y; Liu W
AAPS PharmSciTech; 2017 May; 18(4):997-1008. PubMed ID: 28101726
[TBL] [Abstract][Full Text] [Related]
12. An insight on ophthalmic drug delivery systems: Focus on polymeric biomaterials-based carriers.
Shafiq M; Rafique M; Cui Y; Pan L; Do CW; Ho EA
J Control Release; 2023 Oct; 362():446-467. PubMed ID: 37640109
[TBL] [Abstract][Full Text] [Related]
13. Multifunctional carboxymethyl chitosan derivatives-layered double hydroxide hybrid nanocomposites for efficient drug delivery to the posterior segment of the eye.
Wang Y; Zhou L; Fang L; Cao F
Acta Biomater; 2020 Mar; 104():104-114. PubMed ID: 31931169
[TBL] [Abstract][Full Text] [Related]
14. [Design of Novel Ophthalmic Formulation Containing Drug Nanoparticles and Its Usefulness as Anti-glaucoma Drugs].
Nagai N
Yakugaku Zasshi; 2016; 136(10):1385-1390. PubMed ID: 27725388
[TBL] [Abstract][Full Text] [Related]
15. Combination of self-assembling system and N,O-carboxymethyl chitosan improves ocular residence of anti-glaucoma drug.
Kailasam V; Kumara BN; Prasad KS; Nirmal J
Eur J Pharm Biopharm; 2024 Apr; 197():114208. PubMed ID: 38336235
[TBL] [Abstract][Full Text] [Related]
16. Chitosan/hydroxyethyl cellulose inserts for sustained-release of dorzolamide for glaucoma treatment: In vitro and in vivo evaluation.
Franca JR; Foureaux G; Fuscaldi LL; Ribeiro TG; Castilho RO; Yoshida MI; Cardoso VN; Fernandes SOA; Cronemberger S; Nogueira JC; Ferreira AJ; Faraco AAG
Int J Pharm; 2019 Oct; 570():118662. PubMed ID: 31491481
[TBL] [Abstract][Full Text] [Related]
17. Controlled release, chitosan-tethered luteolin phytocubosomes; Formulation optimization to in-vivo antiglaucoma and anti-inflammatory ocular evaluation.
Omran S; Elnaggar YSR; Abdallah OY
Int J Biol Macromol; 2024 Jan; 254(Pt 3):127930. PubMed ID: 37944733
[TBL] [Abstract][Full Text] [Related]
18. A nanoparticle formulation of disulfiram prolongs corneal residence time of the drug and reduces intraocular pressure.
Nagai N; Yoshioka C; Mano Y; Tnabe W; Ito Y; Okamoto N; Shimomura Y
Exp Eye Res; 2015 Mar; 132():115-23. PubMed ID: 25633346
[TBL] [Abstract][Full Text] [Related]
19. Brinzolamide loaded chitosan-pectin mucoadhesive nanocapsules for management of glaucoma: Formulation, characterization and pharmacodynamic study.
Dubey V; Mohan P; Dangi JS; Kesavan K
Int J Biol Macromol; 2020 Jun; 152():1224-1232. PubMed ID: 31751741
[TBL] [Abstract][Full Text] [Related]
20. Dorzolamide-loaded PLGA/vitamin E TPGS nanoparticles for glaucoma therapy: Pharmacoscintigraphy study and evaluation of extended ocular hypotensive effect in rabbits.
Warsi MH; Anwar M; Garg V; Jain GK; Talegaonkar S; Ahmad FJ; Khar RK
Colloids Surf B Biointerfaces; 2014 Oct; 122():423-431. PubMed ID: 25159319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
